Experience in the use of olaparib poly (ADP-ribose) polymerase inhibitors in maintenance therapy of BRCA-associated ovarian cancer

Aim to study the frequency of BRCA1/2 gene mutations , efficacy ovarian cancer therapy depending on presence as well olaparib maintenance in BRCAassociated cancer. Material and Methods. The retrospective analysis included 355 patients with high-grade, stage I–IV serous examination for a mutation was carried out within framework program “Improvement molecular genetic diagnostics Russian Federation order increase effectiveness antitumor treatment”. Results. Mutations genes were detected 98 (27.6 %) patients. BRCA1+ 62 230 stages IIIC–IV (27.0 %), BRCA2 – 9 (3.9 %). In III–IV, BRCA absent 159 (69.1 median time progression III–IV disease BRCA1 22.0 months, 27.0 without 17.0 life expectancy 70.0; 65.0 45.0 respectively. Patients carcinoma high-grade divided into two groups. first group (6 26 patients, 23.1 consisted carcinoma, who received after 1st line chemotherapy, second (20 76.9 mode 2 or more lines chemotherapy. Conclusion. significantly increased cancer, primary cytoreduction improved both overall survival this Maintenance is appropriate treatment than subsequent ones.